Last edition
News about Clinical Trials
FIU Researchers Advance Functional Precision Medicine for Hard to Treat Cancers
FIU researchers are advancing functional precision medicine for hard-to-treat cancers, with new funding accelerating drug sensitivity testing to identify personalized, effective therapies beyond conventional genetic approaches.
Clinical Trials | 22/01/2026 | By News Bureau
Moderna and Merck Show Durable Five-Year Benefit for Intismeran-KEYTRUDA in Melanoma
At a median five-year follow-up, intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 49 percent versus KEYTRUDA alone, with further data expected and multiple late-stage trials ongoing across tumour types.
Clinical Trials | 22/01/2026 | By News Bureau
Olatec Therapeutics presented MJFF-funded preclinical data showing its oral NLRP3 inhibitor dapansutrile delivered disease-modifying effects across two translational Parkinson’s disease mouse models.
Clinical Trials | 21/01/2026 | By News Bureau
Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme
Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.
Clinical Trials | 20/01/2026 | By News Bureau
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
Clinical Trials | 19/01/2026 | By News Bureau
ISCR Urges Union Budget 2026 to Focus on Boosting India's Clinical Research Ecosystem
ISCR seeks higher funding, AI-led innovation and regulatory reforms in Union Budget 2026 to boost global competitiveness and accelerate patient access to therapies.
Clinical Trials | 17/01/2026 | By News Bureau
First Patient Dosed in New Beat AML Sub-Study Testing Triplet Therapy
Blood Cancer United launches a new Beat AML sub-study evaluating ficlatuzumab with venetoclax and azacitidine for newly diagnosed older adults with acute myeloid leukemia.
Clinical Trials | 15/01/2026 | By News Bureau
Boehringer Ingelheim Begins Phase IIa Trial of BI 765423 in IPF
Boehringer Ingelheim has initiated a Phase IIa clinical trial of BI 765423, a novel IL-11–targeting monoclonal antibody, in patients with Idiopathic Pulmonary Fibrosis (IPF), advancing its efforts to develop new treatment options for progressive fibrotic lung diseases.
Clinical Trials | 15/01/2026 | By News Bureau
UK Sees Surge in Clinical Trials as MHRA Unveils Faster Approval Pathways
UK is boosting its global clinical trials appeal through rising trial activity and new fast-track MHRA regulations, enabling quicker approvals, earlier patient access and increased investment.
Clinical Trials | 14/01/2026 | By News Bureau
First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC
The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.
Clinical Trials | 14/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy